AstraZeneca’s Early Science Ambition
Our bold ambition is to defy the natural course of respiratory and immunological diseases, to slow disease progression, to achieve disease modification and to drive remission by targeting core disease drivers.
Our ambition is to transform the treatment of respiratory disease; to eliminate COPD as a leading cause of death by slowing and ultimately reversing the progression of the disease ; to eliminate exacerbations in asthma and, in severe asthma, achieve clinical remission. In addition, we are also investigating other respiratory conditions with high unmet need, including idiopathic pulmonary fibrosis and chronic cough.
Watch the video to see how we are leading the science in COPD.
In immunology, our understanding of the imbalanced immune system in chronic lung diseases is being applied to immune-mediated inflammatory diseases that share key common pathways. Our ambition is to drive clinical remission and eventually cures in areas of high unmet need including rheumatology, dermatology and gastroenterology.
Watch the video to find out more about our work on immune-mediated diseases.
Across Respiratory and Immunology, we are slowing disease progression and driving remission by targeting core disease drivers. To drive greater efficacy, we employ a precision medicine approach from the start; we use genetics, artificial intelligence and machine learning to identify novel unbiased targets and have developed an expanded toolbox of therapeutic modalities to ensure no target is undruggable.
In addition, we are using novel, enhanced diagnostics and endpoints as well as advances in imaging and digital health solutions to deliver our innovative clinical trials and contribute to our ambition to provide life-changing treatments that enable patients to live their lives without limits.
 Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis and Management of Chronic Obstructive Pulmonary Disease. 2022 Report. Available from: https://goldcopd.org/2022-gold-reports-2/.